Glycogen storage disease type II

Results: 169



#Item
121Krabbe disease / Glycogen storage disease type II / Galactosylceramidase / Lysosomal storage disease / Newborn screening / Association of Public Health Laboratories / Centers for Disease Control and Prevention / Health / Rare diseases / Medicine

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY Volume 3, No. 1

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2014-02-26 14:19:56
122Krabbe disease / Lysosomal storage disease / Glycogen storage disease type II / Galactosylceramidase / Newborn screening / Association of Public Health Laboratories / Centers for Disease Control and Prevention / Health / Rare diseases / Medicine

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING December 2013

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2013-12-12 07:55:53
123Krabbe disease / Lysosomal storage disease / Glycogen storage disease type II / Galactosylceramidase / Newborn screening / Association of Public Health Laboratories / Acid alpha-glucosidase / Centers for Disease Control and Prevention / Health / Rare diseases / Medicine

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING Volume 2, No. 2

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2013-05-21 09:46:35
124Krabbe disease / Lysosomal storage disease / Glycogen storage disease type II / Galactosylceramidase / Newborn screening / Association of Public Health Laboratories / Acid alpha-glucosidase / Centers for Disease Control and Prevention / Health / Rare diseases / Medicine

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING August 2013

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2013-08-26 07:08:24
125Krabbe disease / Glycogen storage disease type II / Galactosylceramidase / Newborn screening / Lysosomal storage disease / Association of Public Health Laboratories / Centers for Disease Control and Prevention / Health / Rare diseases / Medicine

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENC YVolume 3, No. 2

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2014-05-29 10:51:40
126Glycogen storage disease type II / Genzyme / Allergy / Medicine / Health / Alglucosidase alfa

HIG H LIG H TS O F PRES CRIBING INFO RMATIO N Th e s e hig hlig hts do n ot include a ll the information needed to u se MYO ZYME s afe ly and effectively . See full prescribing i nformation for MYO ZYME. MYO ZYME® (a l

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-05-27 14:10:42
127Lysosomal storage diseases / Glycogen storage disease type II / Hepatology / National Institutes of Health / National Institute of Arthritis and Musculoskeletal and Skin Diseases / Acid alpha-glucosidase / Alglucosidase alfa / Arthritis / Weakness / Medicine / Health / Rare diseases

JANUARY[removed]UNDERSTANDING POMPE DISEASE Pompe (POM-pay) disease, also known as glycogen storage disease type II or acid maltase deficiency, is a

Add to Reading List

Source URL: www.niams.nih.gov

Language: English - Date: 2013-05-22 13:44:51
128Autoimmune diseases / Rare diseases / National Institute of Arthritis and Musculoskeletal and Skin Diseases / Arthritis / Rheumatology / NIH Intramural Research Program / Glycogen storage disease type II / Arthritis Foundation / Rheumatoid arthritis / Health / Medicine / National Institutes of Health

NIAMS IRPartners Spring/Summer[removed]A newsletter for

Add to Reading List

Source URL: www.niams.nih.gov

Language: English - Date: 2011-10-31 10:43:00
129Pharmacology / Bethesda /  Maryland / Cancer research / Nursing research / Glycogen storage disease type II / Food and Drug Administration / Rare disease / Medicine / Health / National Institutes of Health

Microsoft Word - PatAdvoDayPhotos_to upload on webpage_final edits_4[removed]xml

Add to Reading List

Source URL: www.fda.gov

Language: English
130Glycogen storage disease type II / Hepatology / Alglucosidase alfa / Genzyme / Pharmacist / Medicine / Health / Rare diseases

risk-management-plan.pdf Page 1 of 10 Lumizyme® (alglucosidase alfa[removed]Risk Evaluation and Mitigation Strategy (REMS) Initial REMS Approval: [removed]Most Recent Modification: [removed]

Add to Reading List

Source URL: www.fda.gov

Language: English
UPDATE